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Background
HIV-1 envelope (Env) gp120 is an important target for
neutralizing antibody (Ab) responses against the virus.
However, developing gp120 vaccines that elicit potent
and broad neutralizing Abs has proven to be a formid-
able challenge. The envelope gp120 is highly glycosy-
lated and carbohydrate moieties play an important role
in modulation of immunobiological property of HIV-1
Env gp120. Previously, removal of a specific N-linked
glycan at residue 448 by N to Q mutation (N448Q) has
been found to enhance in vitro antigenicity of neutraliz-
ing epitopes in the V3 loop. In the present study we
examined immunogenicity of mutant gp120 in mice.
Methods
Two immunization protocols were tested. First, using
plasmid DNA expressing gp120BH10 followed by pro-
tein boost with QS-21 adjuvant. Second, gp120 was
administered as an immune complex with antibody in
DDA/MPL adjuvant. Cellular responses were measured
using spleen cell proliferation and cytokine production
by Bio-Plex multiplex assay. Sera were evaluated for
antibody binding via ELISA and neutralization activity
via TZM-bl assay.
Results
With the DNA prime/protein boost protocol, N448Q
gp120 mutant induced higher levels of gp120 specific
lymphoproliferation and cytokine production as com-
pared to wild type. However, both mutant and wild type
gp120s failed to generate anti-V3 Abs and virus-neutra-
lizing Ab response. In contrast, immunization with
mutant gp120 in complex with mAb 654 elicited higher
titers of neutralizing Abs activity than the wild type
counterpart. Neutralizing activity was directed to V3
and other undefined neutralizing epitopes. Improved
immunogenicity of immune complexes correlated with
increased reactivity and proteolytic resistance of V3 and
other Ab epitopes.
Conclusion
These data demonstrate the advantage of combining
site-specific N-glycan removal and immune complex
formation as a novel vaccine strategy to improve immu-
nogenicity of Ab epitopes on critical regions of HIV-1
gp120. Importantly, epitope immunogenicity is governed
not only by its antigenicity but also by its stability
against proteolytic degradation.
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